Ueda Taeko
   Department   School of Medicine  Obstetrics and Gynecology, Clinical Medical Sciences
Article types journal article
Language English
Peer review Non peer reviewed
Title Clinical Efficacy of Aprepitant in Patients with Gynecological Cancer after Chemotherapy Using Paclitaxel and Carboplatin.
Journal Formal name:Anticancer research
Abbreviation:Anticancer Res
ISSN code:17917530/02507005
Domestic / ForeginForegin
Publisher International Institute of Anticancer Research
Volume, Issue, Page 35(8),4527-4534頁
Author and coauthor Maehara Miyako, Ueda Taeko, Miyahara Daisuke, Takahashi Yoko, Miyata Kohei, Nam Sung Ouk, Katsuda Takahiro, Kondo Haruhiko, Miyamoto Shingo
Publication date 2015/08
Summary AIM:This study aimed to evaluate the efficacy of aprepitant, a neurokinin (NK)1 receptor antagonist, on chemotherapy-induced nausea and vomiting (CINV).PATIENTS AND METHODS:A randomized, open-labeled, parallel-design study was undertaken in gynecologic-cancer (GC) patients at the Fukuoka University Hospital. Twenty-three patients were divided into without (group A) or with aprepitant (Group B) in the first cycle of paclitaxel and carboplatin (TC) therapy. From the second cycle onwards, all patients used aprepitant. Statistical significance was assessed using McNemar and Chi-square tests.RESULTS:In the first cycle, the prevalence of a complete response, no episodes of nausea or food intake in group B was significantly increased compared to group A. No significant difference in the prevalence of a complete response or food intake situation was found from the second cycle onwards.CONCLUSION:Combination of aprepitant with standard anti-emetic therapy may contribute to prevention of CINV in TC therapy for GC patients.
PMID 26168497